PDCD1 and hepatocellular carcinoma: The findings of the present study are broadly consistent with a retrospective study [2] of 70 patients with advanced HCC that assessed the antitumour efficacy of HAIC combined with PD-1 inhibitors plus lenvatinib in patients with advanced HCC.